Borecki IB, Province MA, Rao DC Inferring a major gene for quantitative traits by using segregation analysis with tests on transmission probabilities: how often do we miss? Am J Hum Genet. 1995 Jan;56(1):319-26.
Borecki IB, Province MA, Rao DC Power of segregation analysis for detection of major gene effects on quantitative traits. Genet Epidemiol. 1994;11(5):409-18.
Djoussé L, Ellison RC, Zhang Y, Arnett DK, Sholinsky P, Borecki I Relation between dietary fiber consumption and fibrinogen and plasminogen activator inhibitor type 1: The National Heart, Lung, and Blood Institute Family Heart Study. Am J Clin Nutr. 1998 Sep;68(3):568-75.
Garg UC, Arnett DK, Evans G, Eckfeldt JH No association between factor V Leiden mutation and coronary heart disease or carotid intima media thickness: the NHLBI Family Heart Study. Thromb Res. 1998 Mar 15;89(6):289-93.
Hopkins PN, Heiss G, Ellison RC, Province MA, Pankow JS, Eckfeldt JH, Hunt SC Coronary artery disease risk in familial combined hyperlipidemia and familial hypertriglyceridemia: a case-control comparison from the National Heart, Lung, and Blood Institute Family Heart Study. Circulation. 2003 Aug 5;108(5):519-23. Epub 2003 Jul 7.
Hunt KJ, Heiss G, Sholinsky PD, Province MA Familial history of metabolic disorders and the multiple metabolic syndrome: the NHLBI family heart study. Genet Epidemiol. 2000 Dec;19(4):395-409.
Lin JP, Myers RH, Almasy L, Coon HH, Arnett DK, Hong Y, Hunt SC Linkage of the cholesterol 7alpha-hydroxylase gene and low-density lipoprotein cholesterol conditional on apolipoprotein E association: the National Heart, Lung, and Blood Institute Family Heart Study. Chin Med J (Engl). 2005 Mar 5;118(5):362-9.
Pankow JS, Arnett DK, Borecki IB, Hunt SC, Eckfeldt JH, Folsom AR, Djoussé L Lack of association between the angiotensin-converting enzyme insertion/deletion polymorphism and plasminogen activator inhibitor-1 antigen levels in the National Heart, Lung, and Blood Institute Family Heart Study. Blood Coagul Fibrinolysis. 2000 Sep;11(6):551-8.
Siegmund KD, Todorov AA, Province MA A frailty approach for modelling diseases with variable age of onset in families: the NHLBI Family Heart Study. Stat Med. 1999 Jun 30;18(12):1517-28.
Tsai MY, Arnett DK, Eckfeldt JH, Williams RR, Ellison RC Plasma homocysteine and its association with carotid intimal-medial wall thickness and prevalent coronary heart disease: NHLBI Family Heart Study. Atherosclerosis. 2000 Aug;151(2):519-24.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
